1. In Vivo
  2. >>Leadership

AZ’s Susan Galbraith On What’s Next In The Cancer Pipeline

 
• By Alexandra Shimmings

One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to In Vivo about what’s coming next from the UK major’s cancer pipeline.    

Missile
AZ is aiming to pick the right target for the right kind of cancer and pair it with the right warhead • Source: Shutterstock

Success is said to breed success, but for AstraZeneca PLC, recent triumphs for its oncology portfolio are not to be taken for granted. As well as diversifying its pipeline through select deals, such as the recent acquisition of TeneoTwo, Inc. to boost its hemato-oncology presence, the company is banking on success with its pipeline of novel anticancers to take its offering to the next level. Oncology chief Susan Galbraith talked to In Vivo about some of the more promising earlier candidates coming through the pipeline.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

‘I Want Everything To Go Faster’: Medidata’s CEO On Pushing The Strategic Accelerator

 
• By Jo Shorthouse

Appointed CEO 12 months ago, Anthony Costello wasted no time in orchestrating strategic change at Medidata. He talked to In Vivo about the art of the pivot and how to constantly push boundaries.

From Brain Waves to Better Outcomes: Inside Alto Neuroscience’s Biomarker Strategy

 
• By David Wild

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.

Merck’s Digital Biomarker Strategy For Commercial Gains In Neurology

 
• By Jo Shorthouse

The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA, Darmstadt, Germany is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.

Rising Leaders 2025: Gunnar Sachs On Pursuing The Legal Path To Life Science Business Growth

 
• By Ashley Yeo

Not everyone welcomes change as much as lawyers do. There is much of that ahead for Clifford Chance partner and life science expert Gunnar Sachs as he negotiates political shifts and surfs the rising tide of legal challenges to help companies stay compliant and competitive. Musicianship provides the work-life balance.

More from In Vivo

Merck’s Digital Biomarker Strategy For Commercial Gains In Neurology

 
• By Jo Shorthouse

The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA, Darmstadt, Germany is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.

Rising Leaders 2025: Gunnar Sachs On Pursuing The Legal Path To Life Science Business Growth

 
• By Ashley Yeo

Not everyone welcomes change as much as lawyers do. There is much of that ahead for Clifford Chance partner and life science expert Gunnar Sachs as he negotiates political shifts and surfs the rising tide of legal challenges to help companies stay compliant and competitive. Musicianship provides the work-life balance.

Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision Therapies

 
• By Jo Shorthouse

In Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.